Open AccessCH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
Author(s) -
Zehui Liu,
Wanyan Wang,
Ting-Yu Huang,
Cunfang Wang,
Ying Huang,
Yong Tang,
Jin Huang
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0222757
Subject(s) - neuroprotection , viability assay , pharmacology , dementia , medicine , neurite , hydrolysate , alzheimer's disease , reactive oxygen species , disease , oxidative stress , apoptosis , chemistry , biochemistry , in vitro , hydrolysis
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and is the most common type of cognitive impairment and dementia. There is a pressing need to improve the clinical efficacy and quality of life for AD patients, as limited treatments options for AD patients have been developed until now. In this study, we aim to investigate the protective effect of CH(II), a cerebroprotein hydrolysate consisted of abundant biological peptides, on preclinical model of AD. We found that CH(II) treatment effectively protects oxygen glucose deprivation (OGD)-induced N2A cell viability impairment and cell apoptosis. In addition, CH(II) significantly reduces H 2 O 2 -induced ROS accumulation and exhibits the protective activities against H 2 O 2 -induced oxidative injury. Intriguingly, we found that CH(II) treatment can effectively promote neurite outgrowth of N2A cells. Moreover, CH(II) obviously improve the cognitive and memorial function in scopolamine-induced amnesia mice model. Taken together, this study provides evidences of the neuroprotective activities of CH(II) and offers a potential therapeutic strategy for AD patients.